All In Biotech

NDA 203108 · Boehringer Ingelheim

Striverdi Respimat

Olodaterol Hydrochloride · Inhalation

Novel

Last checked: Nov 20, 2026Latest source record: Dec 27, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Jul 31, 2014

Approved uses

1

Original approval plus efficacy supplements

Registered trials

79

28 Phase 3, 0 recruiting

FAERS reports

369

183 serious, 19 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 3, 2025.

STRIVERDI RESPIMAT Inhalation Spray is a long-acting beta 2 -adrenergic agonist (LABA) indicated for: The long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. ( 1.1 ) Important limitations: STRIVERDI RESPIMAT is NOT indicated to treat acute deterioration of COPD. ( 1.2 ) STRIVERDI RESPIMAT is NOT indicated to treat asthma. ( 1.2 ) 1.1 Maintenance Treatment of COPD STRIVERDI RESPIMAT is a long-acting beta 2 -agonist indicated for long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. 1.2 Important Limitations of Use STRIVERDI RESPIMAT is not indicated to treat acute deteriorations of COPD [see Warnings and Precautions (5.2) ] . STRIVERDI RESPIMAT is not indicated to treat asthma. The safety and effectiveness of STRIVERDI RESPIMAT in asthma have not been established.

Mechanism: Olodaterol is a long-acting beta 2 -adrenergic agonist (LABA). The compound exerts its pharmacological effects by binding and activation of beta 2 -adrenoceptors after topical administration by inhalation. Activation of these receptors in the airways results in a stimulation of intracellular adenyl cyclase, an enzyme that mediates the synthesis of cyclic-3', 5' adenosine monophosphate (cAMP). Elevated levels of cAMP induce bronchodilation by relaxation of airway smooth muscle cells. In vitro studies have shown that olodaterol has 241-fold greater agonist activity at beta 2 -adrenoceptors...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • STRIVERDI RESPIMAT · OLODATEROL HYDROCHLORIDE EQ 0.0025MG BASE/INH · SPRAY, METERED, INHALATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Olodaterol" as an intervention, any sponsor and status, largest first.

All 79 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea54
  • cough35
  • off label use32
  • drug ineffective30
  • asthma14
  • chest pain13
  • chronic obstructive pulmonary disease13
  • pneumonia13
  • asthenia12
  • chest discomfort11
  • dizziness10
  • palpitations10

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20111
201420
201556
201653
201747
201822
201929
202025
202129
202222
202322
202415
202515
202613

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Striverdi Respimat (Olodaterol HCl)

2024 spending

$4.9M

Beneficiaries

3,519

12,563 claims

Per beneficiary

$1,396

$63.86 per unit

View as table
YearSpending
2020$3,158,540
2021$4,688,999
2022$5,033,627
2023$5,086,062
2024$4,912,708

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 80 on PubMed

Sponsor: Boehringer Ingelheim

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.